196 related articles for article (PubMed ID: 28842744)
1. Multisite tumor sampling enhances the detection of intratumor heterogeneity at all different temporal stages of tumor evolution.
Erramuzpe A; Cortés JM; López JI
Virchows Arch; 2018 Feb; 472(2):187-194. PubMed ID: 28842744
[TBL] [Abstract][Full Text] [Related]
2. A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma.
Lopez JI; Cortes JM
F1000Res; 2016; 5():385. PubMed ID: 27127618
[TBL] [Abstract][Full Text] [Related]
3. Multisite tumor sampling: a new tumor selection method to enhance intratumor heterogeneity detection.
López JI; Cortés JM
Hum Pathol; 2017 Jun; 64():1-6. PubMed ID: 28237785
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Tumor Eco-Evolution in Renal Cell Carcinoma Sampling.
López-Fernández E; López JI
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518081
[TBL] [Abstract][Full Text] [Related]
5. Detection of Intratumor Heterogeneity in Modern Pathology: A Multisite Tumor Sampling Perspective.
Cortés JM; de Petris G; López JI
Front Med (Lausanne); 2017; 4():25. PubMed ID: 28321395
[TBL] [Abstract][Full Text] [Related]
6. Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC).
Guarch R; Cortés JM; Lawrie CH; López JI
F1000Res; 2016; 5():2020. PubMed ID: 27635226
[TBL] [Abstract][Full Text] [Related]
7. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level.
Manini C; López-Fernández E; Lawrie CH; Laruelle A; Angulo JC; López JI
Curr Urol Rep; 2022 Jun; 23(6):93-97. PubMed ID: 35416538
[TBL] [Abstract][Full Text] [Related]
8. Towards Personalized Sampling in Clear Cell Renal Cell Carcinomas.
Manini C; López-Fernández E; López JI
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884442
[TBL] [Abstract][Full Text] [Related]
9. High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma.
Guarch R; Lawrie CH; Larrinaga G; Angulo JC; Pulido R; López JI
Ann Diagn Pathol; 2018 Jun; 34():27-30. PubMed ID: 29661723
[TBL] [Abstract][Full Text] [Related]
10. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
Zhang LL; Kan M; Zhang MM; Yu SS; Xie HJ; Gu ZH; Wang HN; Zhao SX; Zhou GB; Song HD; Zheng CX
Int J Cancer; 2017 Jan; 140(1):103-108. PubMed ID: 27646734
[TBL] [Abstract][Full Text] [Related]
11. Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity.
McBride M; Rida PC; Aneja R
Mol Aspects Med; 2015 Nov; 45():3-13. PubMed ID: 26024970
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival.
Morris LG; Riaz N; Desrichard A; Şenbabaoğlu Y; Hakimi AA; Makarov V; Reis-Filho JS; Chan TA
Oncotarget; 2016 Mar; 7(9):10051-63. PubMed ID: 26840267
[TBL] [Abstract][Full Text] [Related]
13. Intratumor heterogeneity: evolution through space and time.
Swanton C
Cancer Res; 2012 Oct; 72(19):4875-82. PubMed ID: 23002210
[TBL] [Abstract][Full Text] [Related]
14. Intratumor heterogeneity: A new perspective on colorectal cancer research.
Zheng Z; Yu T; Zhao X; Gao X; Zhao Y; Liu G
Cancer Med; 2020 Oct; 9(20):7637-7645. PubMed ID: 32853464
[TBL] [Abstract][Full Text] [Related]
15. Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach.
Goto T; Hirotsu Y; Amemiya K; Mochizuki H; Omata M
Cancers (Basel); 2018 Jun; 10(7):. PubMed ID: 29932159
[TBL] [Abstract][Full Text] [Related]
16. Clinical and translational relevance of intratumor heterogeneity.
Goyette MA; Lipsyc-Sharf M; Polyak K
Trends Cancer; 2023 Sep; 9(9):726-737. PubMed ID: 37248149
[TBL] [Abstract][Full Text] [Related]
17. Precision sampling fuels precision oncology: an evolutionary perspective.
Manini C; López-Fernández E; López JI
Trends Cancer; 2021 Nov; 7(11):978-981. PubMed ID: 34493466
[TBL] [Abstract][Full Text] [Related]
18. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.
López JI; Pulido R; Cortés JM; Angulo JC; Lawrie CH
Pathol Res Pract; 2018 Aug; 214(8):1110-1114. PubMed ID: 29910061
[TBL] [Abstract][Full Text] [Related]
19. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.
Hsieh JJ; Manley BJ; Khan N; Gao J; Carlo MI; Cheng EH
Semin Cell Dev Biol; 2017 Apr; 64():98-106. PubMed ID: 27615548
[TBL] [Abstract][Full Text] [Related]
20. A multi-site cutting device implements efficiently the divide-and-conquer strategy in tumor sampling.
Lopez JI; Cortes JM
F1000Res; 2016; 5():1587. PubMed ID: 27540472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
